Granard Pharmaceuticals Sales and Marketing Launches Respiratory Products for Ritedose Pharmaceuticals, LLC.

Share Article

Granard Pharmaceuticals enters into agreement with Ritedose Corporation

News Image

Granard Pharmaceuticals Sales & Marketing announced today it has entered into an agreement with The Ritedose Corporation to market and sell its line of respiratory inhalation products via a newly formed subsidiary Ritedose Pharmaceuticals, LLC.

Since 1998, The Ritedose Corporation (TRC) has been the leader in blow-fill seal (BFS) contract manufacturing of small fill volume pharmaceutical unit dose sterile and non-sterile liquids. TRC specializes in manufacturing inhalation products, eye drops, ear drops, and unit dose oral liquids. Over the past two years, TRC has provided more than 50% of the US market volume in the unit dose respiratory sector with approximately 1 billion unit dose vials of production.

In January 2012, TRC launched Ritedose Pharmaceuticals, LLC to begin providing direct to market access to its line of respiratory products by leveraging TRC’s high quality and compliance as well as consistent and reliable supply chain.

A privately held company Granard has provided trade, distribution, sales, and marketing representation to both brand and generic pharmaceutical companies for over 15 years. Granard provides manufacturers the opportunity to utilize the brand & generic relationships they have built over the years within the chains, wholesalers, distributors and mail order customers. Granard helps clients achieve rapid market penetration by leveraging our established relationships with more than 120 national points of distribution, including pharmaceutical wholesalers, generic distributors, retail chains and mail order pharmacies.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Armand Crupi, Executive Vice President